Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

Saved in:
Bibliographic Details
Published inBlood cancer journal (New York) Vol. 11; no. 2; pp. 19 - 4
Main Authors Derman, Benjamin A., Stefka, Andrew T., Jiang, Ken, McIver, Amanda, Kubicki, Tadeusz, Jasielec, Jagoda K., Jakubowiak, Andrzej J.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 05.02.2021
Springer Nature B.V
Nature Publishing Group
Subjects
13/31
14/1
38/77
59/78
631/67/1990/804
692/308/2779/109/1941
82/58
Biomedical and Life Sciences
Biomedicine
Cancer Research
Correspondence
Hematology
Oncology
Online AccessGet full text
ISSN2044-5385
2044-5385
DOI10.1038/s41408-021-00418-2

Cover

More Information
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
ObjectType-Correspondence-3
content type line 23
ISSN:2044-5385
2044-5385
DOI:10.1038/s41408-021-00418-2